A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

NCT07255209 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication IBI362 in Chinese teenagers who are overweight or have obesity along with weight-related health issues.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 180 people Planned (estimated).

Who can join Ages 12–18 · all sexes

Timeline Started 2025-12 · est. completion 2028-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07255209 ↗

Description as written by the study sponsor.

The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.

Treatments tested

Placebo Drug

Placebo SA.QW
IBI362 Drug

IBI362 SA.QW

Main thing measured	Percent Change from Baseline in BMI
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Adolescents With Obesity or Overweight With Weight-Related Comorbidities
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07255209 ↗